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Abstract
Ensuring microbial food safety has always been a challenge at every stages along the
food chain. Meanwhile, healthier community lifestyle demands natural antimicrobial agents
to alleviate the increasing use of chemical preservatives to address microbial contamination.
Antimicrobial resistance issue has also elevated the effort to search for an alternative way to
antibiotics. Bacteriophage (phage) is currently being assessed for its potency as a biocontrol
agent to enhance food safety and as a tool for therapeutic purposes. Prior to phage application,
safety assessment must be conducted in which includes several considerations: from the
discovery, toxicological aspects to the impact of phage ingestion on the gut microbiota. The
gut microbiota which consist of variety of microorganisms inside the human gastrointestinal
tract, cohabitate to each other. Phage is naturally present as one of microorganisms in the
human gut and dynamically interacted with other microbial communities. Phage application
to foods and food-contact surfaces may leave a residue and cause the phages to be ingested,
which in result may alter the gut microbiota composition. Many findings have examined the
relationship between gut microbiota and human health, and so is the factors affecting their
modulation. This review aimed to discuss several points of view from published research
papers related to the challenge of phage to improve food safety and its administration into the
human gut.
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Introduction
Pathogenic bacteria, which can cause infectious diseases to human is getting more
dangerous. Since the bacteria are dynamically evolving from time to time, and in some cases
triggered by the inappropriate use of antibiotics, their ability to survive antimicrobial
treatment has become more powerful and adaptive. The high rate of resistance development
which is not followed by the discovery of new antibiotics can lead to a serious threat. This
event, which is later progressing into multidrug-resistance has become major concern for
public health worldwide. In 2019, the Centers for Disease Control and Prevention (CDC)
reported that more than 2.8 million people suffered from antibiotic resistance infection and
the number of deaths reached more than 35.000 people each year in the United States (CDC
2019).
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Meanwhile, unhygienic condition along the food chain increases the risk of pathogen
exposure to the foodstuffs and food-contact surfaces. Treatments with antimicrobial agents
may not be effective due to the resistance and biofilm formation (Sillankorva et al. 2012;
Lewis 2008). Hence, pathogenic bacteria that contaminates the foodstuff will remain viable
and can cause foodborne infection when it is ingested at a certain amount. In the United
States, the Centers for Disease Control and Prevention (CDC) estimated that there are 48
million cases of foodborne illnesses, of which there are 128.000 hospitalized cases and 3.000
death cases each year. CDC also reported that the major groups causing the illnesses consist
of 31 known pathogens and unspecified agents that are transmitted through foods, in which
21 pathogenic bacteria are listed (CDC 2011a; CDC 2011b; Scallan et al. 2011). Therefore,
in order to reduce foodborne infection and to combat antibiotic resistant bacteria,
development of an alternative way to the antibiotics must be encouraged, one of which is by
utilizing bacteriophage.
Bacteriophage discovery and therapy
Bacteriophage (or phage) was independently discovered in 1915 by Frederick Twort
and later was identified as a virus that can attack bacteria in 1917 by Felix de’Herelle
(McKinstry and Edgar 2005). Phages are the most abundant biological entity on Earth, with
estimated concentration at 1031 (Suttle 2005; Whitman et al. 1998). They can be found
everywhere in any ecosystems, from the human gastrointestinal tract to the oceans (Dion et al.
2020). Caudovirales remains as the largest order of bacteriophages. The International
Committee on Taxonomy of Viruses (ICTV) reported that this order consists of 9 families, 44
subfamilies, 671 genera, and 1967 species. In 2019, ICTV established new list of
Caudovirales families, they are: Myoviridae, Podoviridae, Siphoviridae, Ackermannviridae,
Herelleviridae, Autographviridae, Chaseviridae, Demerecviridae, and Drexlerviridae (ICTV
2019). Several published works had classified phages based on the genome type and
morphology, which are detailed in Table 1.
Figure 1. Escherichia phage T4 (left) and Pseudomonas phage ф8 (right).
The black bar represents 50 nm.
(Courtesy: the late Prof. Dr. Hans-Wolfgang Ackermann of Félix d’Hérelle Reference
Center for Bacterial Viruses, Université Laval, Canada. Available from:
www.phage.ulaval.ca)
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Table 1. Classification of bacteriophages*(Adriaenssens et al. 2020; Barylski et al. 2020a;
Barylski et al. 2020b; Dion et al. 2020; ICTV 2019; Nelson 2014; Ackermann 2011)
ICTV Order ICTV Family
Genome
type
Morphology Examples
Caudovirales Myoviridae dsDNA
(linear)
Icosahedral
head; long,
contractile tail
Enterobacteria phage T4,
Campylobacter phage CP220,
Salmonella phage FelixO1,
Vibrio phage KVP40
Caudovirales Podoviridae dsDNA
(linear)
Icosahedral
head; short tail
Enterobacteria phage T7,
Streptococcus phage Cp1,
Bacillus phage ф29
Caudovirales Siphoviridae dsDNA
(linear)
Icosahedral
head; long, non-
contractile tail
Enterobacteria phage λ,
Mycobacterium phage Brujita,
Staphylococcus phage 77
Caudovirales Ackermannviridae dsDNA Icosahedral
head;
long,contractile
tail (with tail
spikes at the
base of the tail)
Shigella phage AG3,
Salmonella phage 38, Klebsiella
phage 0507KN21, Serratia
phage MAM1
Caudovirales Herelleviridae dsDNA
(linear)
Icosahedral
head; long,
contractile tail
Bacillus phage SPO1,
Staphylococcus phage K,
Listeria phage P100,
Vinavirales Corticoviridae dsDNA
(circular)
Complex
icosahedral
capsid with
internal lipid
membrane
Pseudoalteromonas phage PM2
Mindivirales Cystoviridae Segmented
dsRNA
(linear)
Complex
icosahedral
capsid, lipid
envelope
Pseudomonas phage ф6,
Pseudomonas phage ф8
Tubulavirales Inoviridae ssDNA
(circular)
Filamentous or
rods
Pseudomonas phage Pf1,
Escherichia phage M13, Vibrio
phage CTXф
Levivirales Leviviridae ssRNA
(linear)
Icosahedral
capsid
Enterobacteria phage Qβ,
Enterobacteria phage MS2
Petitvirales Microviridae ssDNA
(circular)
Icosahedral
capsid (12
knoblike
capsomers)
Escherichia phage фX174,
Spiroplasma phage SpV4,
Chlamydia phage Chp1,
Bdellovibrio phage MAC1
- Plasmaviridae dsDNA
(circular)
No capsid, lipid
envelope
Acholeplasma phage L2,
Enterobacteria phage MVL2
Kalamavirales Tectiviridae dsDNA
(linear)
Complex
icosahedral
capsid with
internal lipid
membrane
Bacillus phage AP50,
Pseudomonas phage PRD1,
Gluconobacter phage GC1
*) This classification does not include the following families:Autographviridae (Caudovirales), Chaseviridae
(Caudovirales), Demerecviridae (Caudovirales), Drexlerviridae (Caudovirales),and Plectroviridae (Inoviridae).
Phage is a virus which can specifically kill targeted bacteria. They can infect bacteria
in two ways: lysogenic cycle and lytic cycle. Lysogenic cycle occurs when the environment
is not supportive, in this way, phage will only integrate their genome into the bacteria without
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causing bacterial cell lysis. In contrast, lytic cycle occurs when the environment is supportive,
phage insert their genome and self-replicating inside bacterial host cell until the host lysed
(Forde & Hill 2018). Unfortunately, the utilization of lysogenic cycle of phage remains
under-explored since most of applied research are mainly focused on assessing the use of the
lytic phage instead of lysogenic one to control pathogenic bacteria. Due to its specificity and
the ability to lyse the host cell, lytic phage is often projected to be utilized as natural weapon
against pathogenic bacteria.
Phage therapy has been used in medicine since 1919, yet this approach was once
discredited in the Western World due to the discovery of antibiotics (Summers 2012).
Following the resistance of bacteria, reappraisal for phage therapy practice comes after
several efforts on controlling pathogenic strains showed effective results, such as the use of
lytic phage against Escherichia coli in mice (O’Flynn et al. 2004), chicken (Huff et al. 2002),
calves (Smith et al. 1987), and against Pseudomonas aeruginosa in mouse burn wound model
(McVay et al. 2007). Until recently, scientists have explored various aspects of the lytic
phage from the genome to the metabolome level. Results on phage application in food and
clinical setting were also established, for example: phage application to reduce Salmonella
enterica serovar Enteritidis and Campylobacter jejuni in carcass surface (Goode et al. 2003),
Pseudomonas lactis in raw cow’s milk (Tanaka et al. 2018), Enterobacter sakazakii in
reconstituted infant formula (Kim et al. 2007), Acinetobacter baumannii and Klebsiella
pneumoniae in patient with trauma-related tibial infection (combined with antibiotics) (Nir-
Paz et al. 2019).
Phage therapy offers promising future as an alternative to antibiotics to control
bacterial load and combat antimicrobial resistant bacteria in human and the environment. The
advantages of phage therapy outweigh those of antibiotics, in these aspects: 1) effective
against multidrug-resistant bacteria since phage and antibiotic have different lysis mechanism,
2) substituted microbism does not occur because of phage’s high specificity, 3) adaptive to
bacterial mutation that leads to phage-resistance, 4) economic cost to develop phage system is
relatively cheaper and 5) side effects are uncommon because phages and their derivatives do
not affect eukaryotic cells (Matsuzaki et al. 2005).
However, as an old-fashioned way of treating bacterial infection, phage therapy still
requires further research to establish guidelines or regulations prior to therapeutic use in
human, especially regarding the efficacy and safety following phage exposure.
Key pathogens in human infections: antibiotic resistance and the role of food safety
Global surveillance report published by the World Health Organization (WHO) in
2014 presented the data of bacteria which commonly cause infections in different settings: in
hospital, in the community, and transmitted through the food chain. On the list there are
seven bacteria of international concern, that consist of: Escherichia coli, Klebsiella
pneumoniae, Staphylococcus aureus, Streptococcus pneumoniae, Nontyphoidal Salmonella,
Shigella sp., and Neisseria gonorrhoea. Typical diseases caused by bacteria included in the
report are: urinary tract infections, blood stream infections, wound infections, pneumonia,
meningitis, otitis, foodborne diarrhoea, bacillary dysentery, and gonorrhoea (WHO 2014).
Furthermore, CDC reported 21 known bacterial pathogens which causing foodborne illnesses
and are transmitted through food each year in the United States (CDC 2011b; Scallan et al.
2011), as detailed in Table 2.
In addition, WHO also released the global priority list of resistant pathogens which
carry the urgency for new treatments. The experts divided the priority pathogens into three
main categories: critical, high, and medium. Pathogens that belong to the category of: 1)
critical priority, include: Acinetobacter baumannii, Pseudomonas aeruginosa, and
Enterobacteriaceae (Klebsiella pneumonia, Escherichia coli, Enterobacter spp., Serratia spp.,
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Proteus spp., Providencia spp., and Morganella spp.), 2) high priority, include:Enterococcus
faecium, Staphylococcus aureus, Helicobacter pylori, Campylobacter, Salmonella spp., and
Neisseria gonorrhoeae, and 3) medium priority, include:Streptococcus pneumoniae,
Haemophilus influenzae, and Shigella spp. In their publication, the WHO expert panels
suggested that the discovery of new treatments to these bacteria should not create further
resistance to the existing antibiotics (WHO 2013). Furthermore, CDC classified 18 antibiotic
resistant bacteria and fungi into 3 categories based on the threats to human health, which are:
1) urgent (Carbapenem-resistant Acinetobacter, Candida auris, Clostridioides difficile,
Carbapenem-resistant Enterobacteriaceae, and Drug-resistant Neisseria gonorrhoeae), 2)
serious (Drug-resistant Campylobacter, Drug-resistant Candida, ESBL-producing
Enterobacteriaceae, Vancomycin-resistant Enterococci (VRE), Multidrug-resistant
Pseudomonas aeruginosa, Drug-resistant nontyphoidal Salmonella, Drug-resistant
Salmonella serotype Typhi, Drug-resistant Shigella, Methicillin-resistant Staphylococcus
aureus (MRSA), Drug-resistant Streptococcus pneumoniae, and Drug-resistant Tuberculosis),
and 3) concerning (Erythromycin-Resistant Group A Streptococcus and Clindamycin-
resistant Group B Streptococcus) (CDC 2019).
Table 2. Bacterial pathogens causing foodborne illnesses and their
percentage of annual foodborne illness episodes in the United States
(CDC 2011b; Scallan et al. 2011)
Pathogenic bacteria Foodborne (%)*
Bacillus cereus
Brucella spp.
Campylobacter spp.
Clostridium botulinum
Clostridium perfringens
STEC O157
STEC non–O157
ETEC, foodborne
Diarrheagenic E. coli other than STEC and ETEC
Listeria monocytogenes
Mycobacterium bovis
Salmonella spp., nontyphoidal
S. enterica serotype Typhi
Shigella spp
Staphylococcus aureus
Streptococcus spp. group A
Vibrio cholerae, toxigenic
V. vulnificus
V. parahaemolyticus
Vibrio spp., other
Yersinia enterocolitica
100
50
80
100
100
68
82
100
30
99
95
94
96
31
100
100
100
47
86
57
90
*) percent foodborne among domestically acquired illnesses, based on US
population in 2006
Diseases that are caused by bacterial infection has been taking serious attention since
the resistance is progressing quicker than the development of new antibiotics. Bacteria can
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originally possess the resistance to certain antibiotic (intrinsic resistance), while other types
of bacteria can acquire the resistance genes from the environment (acquired resistance).
Resistance can be acquired as a result of mutation or horizontal gene transfer (Verraes et al.
2013).
Antimicrobial resistant bacteria can be found in human environments, such as in the
soil, plants, water, air, and household area. Food products along the food chain may be
vulnerable to be contaminated by the resistant bacteria because of frequent exposure to the
unhygienic environment. Plant-based products are susceptible to the contamination because
of contaminated soil and irrigation water. One factor that enhances the transfer of resistant
gene in agricultural field is the use of manure to soils. Food animals may not only carry the
resistant bacteria and the resistant gene, but they can also become the endpoint in the
transmission cycle (Thanner et al. 2016). The use of antibiotics, transmission from water or
fecal materials, and contamination during slaughtering process may render bacterial
resistance in animal-based products. Food handler must pay attention to sanitation and
hygiene practices during processing to prevent pre-harvest, post-harvest, or cross-
contamination as they may occur between raw materials.
Food safety plays an important role. Microbial infection which is carried by elements
in the food chain and transmitted to the human body may be the most prominent cause of
infectious disease. The gap of knowledge between the transmission of pathogenic bacteria
from the environment to the human body needs to be more explored to find the solution.
Although the transfer mechanism of resistant genes between bacteria to the environment and
human is almost difficult to be demonstrated due to the complex route, limiting bacterial load
along the food chain can be the most effective way to prevent the spread of antimicrobial
resistance.
Towards implementation of a food safety system, new strategy to control the
emerging pathogens must be developed continuously. In this case, phage intervention
provides advantages to food safety in ways described by Sillankorva et al. (2012), they are: (i)
very specific to the targeted host, (ii) ability to replicating and eliminating themselves, (iii)
adaptive to changing environments, (iv) low toxicity, (v) relatively low cost and easy to
handle, (vi) ability to cope with processing conditions, and (vii) preserving food for a longer
time. Phage application along the food chain covers four major functions: as therapy—to
reduce bacterial colonization in animals, as processing aid—to decontaminate food contact
surfaces and utensils, as antibiotic—to control bacterial load during food processing, and as
preservative—to prevent bacterial contamination and growth during storage of final products
(Greer 2016). Despite the advantages, there are drawbacks following the use of phage in food
setting which has to be further assessed in the safety evaluation.
Nonetheless, to promote surveillance and control of food safety and antimicrobial
resistance, the existence of integrated system is essential. WHO pointed out that there are
significant gaps in the surveillance and data sharing regarding the impact of antibiotic
resistance of foodborne bacteria to the human and animal health (WHO 2014). For example,
the concept of “One Health” system that was initiated by WHO, is an effort that brings
integrated and multisectoral approach to address public health issue, including antimicrobial
resistance and food safety (WHO 2017).
Efficacy and safety concern regarding the application of bacteriophage to human
Food products are essential for human health and well-being. Thus, the development
of phage treatment which will be applied in the food chain must consider any potential issues
regarding the impact of phage use to the human body. Safety assessment had been conducted
by the European Food Safety Authority (EFSA) to evaluate the use of Listeria spp.
phage,which address the safety of phage application from the toxicological aspects, the
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efficacy, the risk of resistance to biocides, bacteriophages, or antimicrobials after phage
exposure, and the risk of phage-spreading in the environment (EFSA 2016). Unfortunately,
there was no detailed assessment in the potency of phage in modulating gut microbiota in
their report yet.
Toxicological safety evaluation evaluates the reaction of chemical substances
following phage treatments. EFSA underlined that phage formulation must not present any
toxicological problems to human (EFSA 2016). Phage consists of DNA or RNA which was
enveloped by protein capsid and can be degraded into amino acids and nucleic acids. The
degradation of phage components must not cause any allergic or toxic reactions to human.
Furthermore, the administration of phage into the human gut will reduce the concentration of
phage due to the low pH of the gastric juice and degradation of protein capsid by digestive
enzymes (Dąbrowska 2019). Phage preparation and formulation is important; purified phage
in proper dilution will contain less protein elements, so that the safety level is increased
(Marza et al. 2006).
In regard to the efficacy, phage application must consider the possibility of bacterial
resistance toward phages. Citorik et al. (2014) reviewed that bacterial resistance can occur as
a result of innate mechanism, as in restriction-modification system, and adaptive mechanism,
as in clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated
(Cas) systems (Citorik et al. 2014; Barrangou et al. 2007; Tock & Dryden 2005). The
efficacy of phage utilization depends on the specificity of phage, the potency of emerging
resistant mutant, and preservation ability to longer shelf life. Phage intervention confers
therapeutic efficacy when phage is selected from these criteria: safe, lytic, polyvalent,
stable,self-replicating, and work effectively when combined in a cocktail (Loc-Carrillo &
Abedon 2011, El Haddad et al. 2016).
The risk of resistance to biocides must be evaluated particularly for the group of
compounds that is frequently used, such as quaternary ammonium compounds (QACs) which
often found to be used in food industry and hospitals. The risk of resistance to phage
following exposure may occur because of the absence or changes of the phage receptor, the
presence of CRISPR-Cas systems which is related to bacterial resistance against phage and
plasmids, and unsuccessful infection. EFSA provided several evidences on the occurrence of
bacterial resistance to phage after long exposure of L. monocytogenes to phage therapy
(EFSA 2016). The risk of resistance to therapeutic antibiotics may vary between strains. In L.
monocytogenes, the resistance to therapeutic antibiotic arises after the assembly of self-
transferable plasmids, mobilizable plasmids and conjugative transposons (Charpentier &
Courvalin 1999). The resistant genes in phage can be detected through molecular analysis by
using sequencing technique.
Safety assessment of phage application must include environmental aspects.
Evaluation of waste components which are resulted from the application of phage should
devise the possible released dosage and information on the exposed site. The inherent
simplicity of phage metabolism supports an idea that phage may be lasted in the environment
for long period of time, but due to phage susceptibility to temperature change, UV light, and
microbial enzymes produced in the environment, phage is likely to undergo inactivation and
break down (EFSA 2016). Still, the possibility of phage reactivation that may initiate the
event of bacterial resistance upon its release from phage preparation should be taken into
consideration.
Route of administration and modulation of gut microbiota
Delivering phage into the human body can be carried out by using phage therapy,
phage-treated foods, food products, and other environment-exposed components. Phage
therapy can be administered through various routes: oral, intravenous, intra-duodenal,
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intramuscular, and rectal (Abedon et al. 2011). Pharmacological factors, both
pharmacokinetics and pharmacodynamics, decide the triumph of phage therapy.
Pharmacokinetics regard the half-life of phage, while pharmacodynamics regards the
virulence of phage (Forde & Hill 2018). Basically, there is a different concept of
pharmacokinetics between chemical drugs and phage therapy. Phage pharmacokinetics
combine the theory of antibacterial pharmacokinetics with consideration of phage behavior
(Dąbrowska 2019). Therefore, all the aspects which are related to ecological perspective of
phage must be regarded.
The oral route is thought to be the most convenient way for the delivery of phage
therapy since oral administration of therapeutic agents is generally fitting in with patients.
Phage that is intended for treating bacterial infection in the gastrointestinal tract as well as
other human organs is often used in this route of administration. One important factor
affecting the success of oral phage delivery is the ability of phage to survive gut transit. The
success of phage in gut transit is commonly examined by detecting phage recovery in feces
after oral application. Literature study of experimental phage showed that they can pass
through the human gut, and their recovery depends verily on the amount of ingested dose
(Dąbrowska 2019). An example of an established success of oral phage therapy was provided
by Leszczyński et al. (2006) in their study for eradicating MRSA colonization in the
gastrointestinal and urinary tract.
Gut microbiota profile has been well-understood to have the correlation with human
health. Hence, phage, as a natural member of gastrointestinal tract, also takes the role in
affecting human health. Metagenomic approach was used to understand the mechanism of gut
microbiota modulation triggered by phage. Temperate phage mostly inhabits healthy gut,
while virulent phage indicates gut dysbiosis (Norman et al. 2015).
Ingestion of certain therapeutic agents will alter gut microbiota composition and bring
impact to the patient’s health. Therapy by using fecal microbiota transplantation (FMT) was
previously showed successful result to relieve the infection of Clostridium difficile (Gupta et
al. 2016). It was believed that FMT contributes to the transfer of lytic phages, either carried
along with their host or conquered a new host within the patient’s gut microbiota (Draper et
al. 2018). Report by Zuo et al. (2017) stated that theFMT therapy alter the enteric viromes
composition (including the Caudovirales or phages) after weeks of treatment in patients with
Clostridium difficile infection (CDI) (Zuo et al. 2017). However, the U.S. Food and Drug
Administration (FDA) in 2019 warns the practice of FMT, as it possesses serious adverse
effect to human with the risk of the transfer of antibiotic resistant bacteria (FDA 2019).
Taking the warning into account, the research on FMT practice should be more reviewed and
explored to answer the safety concern.
Phage therapy can affect the physiological condition due to the increasing or
decreasing amount of phage and bacteria (the changing ratio). An illustration of this impact is
shown in a study comparing the phage composition between the healthy adults and adults
suffer from traveler’s diarrhea. In healthy adults, there were only low concentration of phage
with the type of lambda-like phage, while in the patients, the phage concentration were higher
with the type of T4-like phage (Chibani-chennoufi et al. 2004).
Regulatory hurdles
Phage therapy research and development has been extensively studied to the level of
clinical trials. Regardless of the exploratory study, there is still no official published
guidelines in the Europe and United States that cover the development and clinical study of
phage application. In contrast, there are commercially available phage products which have
been approved for use in food settings. In the agricultural field, there is AgriPhage
(OmniLytics™) which is intended to treat bacterial spot disease in crops. In food industry,
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Listex™ P100 (EBI Food Safety) is used as an antimicrobial agent to control the growth of L.
monocytogenes in cheese, meat, and poultry products which has been granted “Generally
Regarded As Safe (GRAS)” status from the US FDA (EFSA 2016). To obtain the approval,
dossiers which include scientific evidence that address the efficacy and safety of phage
product, including the pharmaceutical, pre-clinical, and clinical aspects, must be submitted to
be reviewed by the experts.
In the Europe, phage therapy is regarded under the European regulatory framework on
biological medicinal product in Directive 2001/83/EC. Due to the dynamic characteristic of
phage, the application dossier must include detailed information on phage characterization
which stated critical parameters to the quality and safety, the specifications and acceptance
criteria, and the flow manufacturing process (Pelfrene et al. 2016). Until recently, there is no
regulatory scheme in which focuses to evaluate the ecological aspect of phage and health care
support in providing phage therapy. In the future, it is expected that the regulatory
development in the United States will grow rapidly since the US FDA currently permitted the
use of phage therapy to support the study at the Center for Innovative Phage Application and
Therapeutics (IPATH) via the Emergency Investigational New Drug scheme (Furfaro et al.
2018).
In conclusion, phage therapy offers promising approach to fight against the spread
and infection of resistant pathogenic bacteria in the food chain. There were many scientific
reports supporting the application of phage therapy in food and clinical settings, but the data
on the mechanism after phage exposure to modulate gut microbiota is still limited. Further
data is still required since phage administration to the human body must be scientifically
proven safe and effective. Scientific evidence regarding the use of phage is also needed as
basic framework for drafting regulatory products.
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